Zecuity (Migraine) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 53 Pages
|Zecuity(偏頭痛治療藥):市場預測與分析 Zecuity (Migraine) - Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 53 Pages||
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Zecuity is the first and only skin patch approved to deliver sumatriptan in patients needing acute treatment to abort their migraines and migraine-related nausea. Zecuity uses a proprietary SmartRelief technology which uses a mild electric current to transport sumatriptan across the skin, a process called iontophoresis. It uses an electric current to pull ionized drug particles through the skin while monitoring the skin's resistance to the transfer of sumatriptan during the four-hour dosing.